title: [Oesophageal cancer: current status of multimodality therapy].
abstract: Multimodality treatment options have been widely promoted in the therapy for locally advanced oesophageal cancer (cT3/4Nx). Generally neoadjuvant chemotherapy and combined radiochemotherapy are frequently used in this setting. The recent meta-analyses evaluating randomised trials of different neoadjuvant therapy protocols prior to surgery for patients with locally advanced oesophageal cancer showed only a modest improvement in survivial of 5-10% survival at 5 years. In contrast, the meta-analyses reveal that patients with excellent histopathological responses seem to highly benefit from neoadjuvant regimens. Patients with poor histopathological responses have no benefit but rather disadvantegeous prognoses. Therefore, predictive markers to allow individualisation of multimodality treatment in locally advanced esophageal cancer are urgently needed.
authors.affiliation: Klinik und Poliklinik für Allgemein-, Viszeral- und Tumorchirurgie; Universität zu Köln, Kerpener Strasse 62, Köln, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Vallböhmer
authors.forename: W
authors.initials: W
authors.lastname: Schröder
authors.forename: J
authors.initials: J
authors.lastname: Brabender
authors.forename: A H
authors.initials: AH
authors.lastname: Hölscher
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D059186:Chemoradiotherapy, Adjuvant; D003131:Combined Modality Therapy; D016503:Drug Delivery Systems; D004938:Esophageal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D057285:Precision Medicine; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents